


Total Synthesis of Ledipasvir (Harvoni®)

J. Med. Chem. **2014**, *57*, 2033-2046.

Bioorg. Med. Chem. **2016**, *24*, 1937-1980.

- Ledipasvir is a potent NS5A inhibitor that is approved for use in combination with sofosbuvir, a nucleotide inhibitor of viral polymerase, for the treatment of chronic hepatitis C virus (HCV) genotype 1 infection
- The combination was discovered and developed at Gilead Sciences and is marketed as the fixed combination with brand name of Harvoni®.



Retro-synthetic Analysis

